Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation

Table 3 Statistical analysis of tumor volume in different imipramine-treated groups and dates

Tukey’s multiple comparisons test Lenvatinib	Mean difference	95.00% CI of difference	Summary	Adjusted P Value
Day 1
0 vs. 5 mg/kg	-4.35	-75.78 to 67.08	ns	0.9885
0 vs. 10 mg/kg	1.967	-69.46 to 73.4	ns	0.9976
5 vs. 10 mg/kg	6.317	-65.11 to 77.75	ns	0.9758
Day 3
0 vs. 5 mg/kg	109.9	38.45 to 181.3	**	0.0012
0 vs. 10 mg/kg	158.4	86.97 to 229.8	****	< 0.0001
5 vs. 10 mg/kg	48.52	-22.91 to 119.9	ns	0.2431
Day 5
0 vs. 5 mg/kg	196.7	125.2 to 268.1	****	< 0.0001
0 vs. 10 mg/kg	293	221.6 to 364.4	****	< 0.0001
5 vs. 10 mg/kg	96.33	24.9 to 167.8	**	0.0051
Day 7
0 vs. 5 mg/kg	286.9	215.4 to 358.3	****	< 0.0001
0 vs. 10 mg/kg	408.6	337.2 to 480.1	****	< 0.0001
5 vs. 10 mg/kg	121.8	50.35 to 193.2	***	0.0003
Day 9
0 vs. 5 mg/kg	487.7	416.2 to 559.1	****	< 0.0001
0 vs. 10 mg/kg	599.1	527.7 to 670.6	****	< 0.0001
5 vs. 10 mg/kg	111.5	40.04 to 182.9	**	0.0010
Day 11
0 vs. 5 mg/kg	509.5	438.1 to 580.9	****	< 0.0001
0 vs. 10 mg/kg	684.9	613.5 to 756.3	****	< 0.0001
5 vs. 10 mg/kg	175.4	104 to 246.8	****	< 0.0001

ISSN: 1475-2867